How the treatment of gastrointestinal tract disorders may be influenced by the kidneys

Czech version

Authors: Merta- P. ^{1 3}
Authors‘ workplace: Fresenius Medical Care ¹; NEFROMED s. r. o. ²; Ústav biologie a lékařské genetiky 1. LF UK v Praze ³
Published in: Gastroent Hepatol 2021; 75(5): 445-450
Category:
doi: https://doi.org/10.48095/ccgh2021445

Overview

The treatment of gastrointestinal tract (GIT) diseases may, under specific conditions, be significantly influenced by the kidneys or by kidney disorders. One of the potential scenarios of such interaction is the concurrent involvement of the kidneys and the GIT organs within one disorder, another option being the negative impact of impaired renal function on the prognosis of the GIT disease and, finally, the need for an adequate choice and dose adjustment of renally eliminated medication to avoid nephrotoxicity. Renal impairment may occur as an adverse effect of the treatment of the GIT condition and may limit further therapy. In this context we have recently focused on the following clinical situations: the development of acute kidney injury during treatment with proton pump inhibitors, renal complications of inflammatory bowel disease management and the development of acute phosphate nephropathy due to the use phosphate containing laxatives. An early identification of the mechanisms leading to renal injury can prevent the development of irreversible renal lesions and facilitate an efficient treatment of the GIT.

Keywords:

acute kidney injury – proton pump inhibitors – treatment of gastrointestinal tract disorders – renal complications of inflammatory bowel disease – acute phosphate nephropathy

Sources

1. Hágendorn R, Farkas N, Vincze A et al. Chronic kidney disease severely deteriorates the outcome of gastrointestinal bleeding: a meta-analysis. Wolrd J Gastroenterol 2017; 23 (47): 8415–8425. doi: 10.3748/wjg.v23.i47.8415.

2. Muriithi AK, Leung N, Valeri AM et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. Am J Kidney Dis 2014; 64 (4): 558–566. doi: 10.1053/j.ajkd.2014.04.027.

3. Xie Y, Bowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016; 27 (10): 3153–3163. doi: 10.1681/ASN.2015121377.

4. Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016; 176 (2): 238–246. doi: 10.1001/jamainternmed.2015.7193.

5. Oikonomou K, Kapsoritakis A, Eleftheriadis T et al. Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (4): 1034–1045. doi: 10.1002/ibd.21468.

6. Mutalib M. Renal involvement in paediatric inflammatory bowel disease. Pediatr Nephrol 2021; 36 (2): 279–285. doi: 10.1007/s00467- 019-04413-5.

7. Ganji-Arjenaki M, Nasri H, Rafieian-Kopaei M. Nephrolithiasis as a common urinary system manifestation of inflammatory bowel diseases; a clinical review and meta-analysis. J Nephropathol 2017; 6 (3): 264–269. doi: 10.15171/jnp.2017.42.

8. Bianchi L, Gaiani F, Bizzarri B et al. Renal lithiasis and inflammatory bowel diseases, an update on pediatric population. Acta Biomed 2018; 89 (9–S): 76–80. doi: 10.23750/abm.v89i9-S.7908.

9. Pardi DS, Tremaine WJ, Sandborn WJ et al. Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998; 93 (4): 504–514. doi: 10.1111/j.1572-0241. 1998.156_b.x.

10. Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis 2016; 10 (2): 226–235. doi: 10.1093/ecco-jcc/jjv138.

11. Teplan V, Honsová E, Lukáš M. Glomerulopatie u pacientů se střevními záněty. Gastroenterol Hepatol 2020; 74 (1): 62–67. doi: 10.14735/amgh202062.

12. Fraser JS, Muller AF, Smith DJ et al. Renal tubular injury is present in acute inflammatory bowel disease prior to the introduction of drug therapy. Aliment Pharmacol Ther 2001; 15 (8): 1131–1137. doi: 10.1046/j.1365-2036.2001. 01041.x.

13. Elloumi H, Ben Slama A, Arfaoui D et al. Renal amyloidosis complicating Crohn‘s disease: report of two cases and review of literature. Tunis Med 2006; 84 (4): 253–255.

14. Ryšavá R. Postižení gastrointestinálního traktu amyloidózou – kdy na ni myslet a jak diagnostikovat. Gastroenterol Hepatol 2019; 73 (2): 154–162. doi: 10.14735/amgh2019154.

15. Muller AF, Stevens PE, McIntyre AS et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005; 21 (10): 1217–1224. doi: 10.1111/j.1365-2036.2005.02462.x.

16. Gisbert JP, Luna M, González-Lama Y. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterologie y Hepatologia 2008; 31 (8): 477–484. doi: 10.1157/13127088.

17. de Jong DJ, Tielen J, Habraken CM et al. 5-Aminosalicylates and effects on renal function in patients with Crohn‘s disease. Inflamm Bowel Dis 2005; 11 (11): 972–976. doi: 10.1097/01.mib.0000185402.65288.19.

18. Weislinger L, Guillo L, D‘Amico F et al. Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021; 33 (9): 1148–1152. doi: 10.1097/MEG.0000000000002008.

19. Meys E, Devogelaer JP, Geubel A et al. Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity. J Rheumatol 1992; 19 (5): 807–809.

20. Stokes MB, Foster K, Markowitz GS et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20 (7): 1400–1406. doi: 10.1093/ndt/gfh832.

21. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008; 16 (3): CD007216. doi: 10.1002/14651858.CD007216.

22. Bailly E, Von Tokarski F, Beau-Salinas F et al. Interstitial nephritis secondary to vedolizumab treatment in Crohn disease and safe rechallenge using steroids: a case report. Am J Kidney Dis 2018; 71 (1): 142–145. doi: 10.1053/ j.ajkd.2017.08.008.

23. Hoffmanová I, Havrda M, Janotová D et al. Akutní fosfátová nefropatie jako komplikace očisty střeva ke koloskopii. Med Praxi 2011; 8 (12): 548–551.

24. Hurst FP, Bohen EM, Osgard EM et al. Association of oral sodium phosphate purgative use with acute kidney injury. J Am Soc Nephrol 2007; 18 (12): 3192–3198. doi: 10.1681/ASN.2007030349.

25. Hassan C, East J, Radaelli F et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019. Endoscopy 2019; 51 (8): 775–794. doi: 10.1055/a-0959-0505.